



Investor Presentation

January 2023

Disclaimer

This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Sonova's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sonova undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

This presentation constitutes neither an offer to sell nor a solicitation to buy any securities. This presentation does not constitute an offering prospectus within the meaning of Article 652a of the Swiss Code of Obligations nor a listing prospectus within the meaning of the listing rules of SIX Swiss Exchange.

Sonova name, products names and logos are registered trademarks of Sonova.

Sennheiser™ is a registered trademark of Sennheiser electronic GmbH & Co. KG used under license by Sonova.

01	Sonova Group & hearing care market	Page 4
02	Sonova's strategy	Page 13
03	ESG Strategy	Page 24
04	Financial Information	Page 28
05	Outlook	Page 37
06	Appendix	Page 40

sonova
HEAR THE WORLD

PHONAK

unitron


AudioNova

SENNHEISER

AB
ADVANCED
BIONICS



Sonova Group & hearing care market



Sonova Group results

Key highlights – HY 2022/23

Sales



CHF 1,847 m
+17.9% in LC
+15.1% in CHF

EPS (adj.)



CHF 4.90 per share
+7.0% in LC
+0.8% in CHF

Sales outlook



+15-19%
growth in LC
in FY 2022/23

EBITA (adj.)



CHF 398.1 m
+3.0% in LC
-2.0% in CHF

Innovation



Phonak Lumity
Successful launch
and positive market
response

EBITA (adj.) outlook



+ 6-10%
growth in LC
in FY 2022/23

Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

Reasons to invest in Sonova

Attractive market

- Attractive secular growth drivers
- Relative resilience to economic cycles
- Good penetration potential in both hearing devices and implants
- Continued potential to innovate “Better Hearing”
- Opportunity to elevate hearing aids to become a “healthy living companion”



Leading market position

- Leading positions in key market segments
- Advanced vertically integrated business model
- Broadest and most advanced product offering
- Global and differentiated distribution network

Strong financials

- Attractive margin with further upside
- Significant capacity for growth investments
- Strong balance sheet
- Solid free cash flow and low tax rate

Note: HI = Hearing Instruments; CI = Cochlear Implants

► **Strong fundamentals and attractive growth potential fully intact**

Our businesses

Company structure and key brands

Hearing Instruments segment

Hearing Instruments



PHONAK **unitron**

Audiological Care



AudioNova

Consumer Hearing



SENNHEISER

Cochlear Implants segment

Cochlear Implants



AB **ADVANCED BIONICS**

Product and service offering

Broadest and most advanced offering of hearing care solutions

SENNHEISER

Consumer Hearing



Premium & True Wireless headphones




Enhanced hearing



Audiophile



Speech-enhanced hearables



PHONAK unitron

Hearing Instruments



Receiver-In-Canal (RIC) hearing instruments



In-The-Ear (ITE) hearing instruments



Behind-The-Ear (BTE) hearing instruments



Roger wireless systems



Cochlear Implants



Sound processors



Cochlear implant systems with electrodes

AudioNova

Audiological Care




Individual diagnostics and analysis

Hearing assessments and counseling, personalized fitting of hearing aids

After care and hearing aid maintenance services

Our footprint

Strong global presence




▶ Active in >100 countries through subsidiaries in >30 countries and a network of independent distributors

Market potential

Market penetration and access to hearing care

Label ■ HI users ■ Hearing impaired w/ no HI ◀ Avg. adoption rate % Note. Bar width = Hearing impaired population



Note: Based on CIA Factbook – Gross domestic product converted to international dollars using purchasing power parity (PPP) rates and divided by total population

► Current penetration levels and improving consumer access to hearing care offers significant upside

Hearing care market

Attractive size and growth potential


Hearing Instruments manufacturing



~ CHF 6-7 bn

Long term growth rate:
~3-5%

1 in the HI market




Audiological Care



~ CHF 11-12 bn

Long term market growth rate:
~ 3-5%

2 in the retail market




Cochlear Instruments manufacturing



~ CHF 1.5 bn

Long term market growth rate:
~5-10%

2/3 in the CI market




Total hearing care market



~ CHF 19-20 bn

Long term market growth rate:
~4-5%

1 in the hearing care market




► **Sonova – #1 position in the overall hearing care market**

Source: Sonova estimates for market size in CY 2021; market CAGR refers to mid-term growth rate post COVID effects

Market trends


Technological advances and expansion of consumer benefits



- ▶ Sonova's opportunity: Innovation leadership to address megatrends and to elevate consumer journey

2

Our strategy



Our strategy

Six strategic pillars




► Consistent implementation of our proven strategy

Lead innovation

Building up competence in artificial intelligence and sensor technology

Innovation framework



Our R&D focus investments

- ➔ Continued expansion of processing power
 - Proprietary processing and connectivity chip technology
- ➔ Elevating algorithms to enhance hearing performance
 - Augmenting existing algorithm technology with AI technologies
- ➔ Broadening functionality towards healthy living benefits
 - Sensor technologies and algorithms
 - Collaborations with medical institutions on comorbidities
- ➔ Expanding consumer applications
 - App development and link into existing ecosystems

▶ Driving innovation to elevate hearing aids – Expanding R&D investments, DD 3-year CAGR

Lead innovation

Successful launch of new hearing instrument platform

Phonak Audéo Lumity – launched in August 2022



Improved speech understanding in challenging hearing situations^{1,2}

Easy to use, rechargeable with new charger



2nd generation of **the world's first waterproof**, rechargeable hearing aid

Universal connectivity to a multitude of Bluetooth enabled devices



¹ Appleton, J. (2020) AutoSense OS 4.0 - significantly less listening effort and preferred for speech intelligibility. Phonak Field Study News retrieved from www.phonakpro.com/evidence.

² Woodward, J and Latzel, M (2022) New implementation of directional beamforming configurations show improved speech understanding and reduced listening effort. Phonak Field Study News in preparation. Expected end of 2022.

► **Significant advancement in speech understanding – Strong customer response**


Expand consumer access – Omni-channel AC network

Proactive approach to serve changing consumer needs and driven by digitalization


Omnichannel strategic pillars



Ecosystem



Evolution of the channel mix



► Sonova Audiological Care in a strong position to successfully drive omni-channel consumer journey

Expand consumer access – AC network expansion

Continued bolt-on acquisitions and greenfield openings

Systematic approach to:

- ➔ Increase store density
- ➔ Optimize the store footprint
- ➔ Enter new growth markets

Balance sheet investments:

Higher spending for bolt-ons

- ➔ Planned cash-out of 70-100 million p.a.

Over CHF 60 million invested in 1H 22/23, adding over 70 POS with focus on the US



M&A

Greenfield

P&L investments:

Expansion with various store formats

Opened over 50 POS in 1H 22/23



Mid-term:

targeting combined MSD to HSD percentage points average annual growth contribution in AC

▶ Continued investment in network expansion – in line with our strategy

Driving growth by elevating commercial execution

Delivering value through customer segmentation, lead generation and training

Achievements*



>20% revenue growth
YoY on competitive accounts



>3x better competitive
conversion rate



2x more customer intakes with
higher propensity to change



35% faster to
close a deal



2x more visits
per week

* Achievements over the past 3 years

The workstreams

Sales



Comprehensive funnel
management for sales
opportunities

- Standard process, tools, metrics and rigorous monitoring



Optimized coverage via
Improved go-to-market and
right-sized number of feet-
on-the street

- Deployed in Major Group Companies in Western Europe and North America
- Asia and remaining Europe in progress

Marketing



Holistic approach to
capitalize customer's
needs and motivation to
do business with Sonova

- Intakes scoring to identify higher propensity to change
- Drive customer engagement via data analytics
- Maximize campaign impact via standard performance framework

Sales Academy



Develop best-in-class sales
organization that shines in
front of customer

- Training program to elevate sales capabilities and skills of our sales teams
- Rolled out in key Group Companies in North America and Europe




Continuous improvement + Daily Management
to guarantee sustainability

► Grow customer base through optimized coverage and commercial execution

Invest in high growth developing markets

China – A unique long-term opportunity



Strong digital AudioNova position

- MyAudioNova app and ecosystem on Tencent's WeChat platform
- 11 online sales channels across all major platforms under AudioNova brand
- Online Phonak flagship stores on Alibaba's T-Mall and JD

Own AudioNova store development

- Successful development of AudioNova store formats in greater Shanghai region
- Launch of World of Hearing store format setting new industry standards in the Chinese B2C HI market

HYSOUND acquisition (closed Dec. 2022)

- Highly professional, national network with medical expertise and high value creation per clinic
- More than 200 clinics and over 650 employees
- Price, sales and number of audiologists per clinic similar to European levels

► Combining our digital platform and own store development with HYSOUND, a strong national player

Continuous improvement

Sonova eXcellence – a structured methodology to continuously improve our core processes

Talent – key ingredient for sustainable success*

- Internal promotion rate from <50% to ~65%
- Voluntary attrition in US stores reduced from >30% to <10%

* Achievements in the past 4 years

Continuous improvement – driving profitability and investment capacity

- Increased labor productivity by >10% p.a. through deployment of Kaizens broadly
- Reduced greenhouse gas emissions by 77% compared to 2017 levels



Growth – maximizing returns*

- Number of customer visits per week doubled, enabling factor 3x increase of competitive visits
- AC client renewal rate up >10% – leveraging existing client base to reduce lead generation cost

* Achievements in the past 3 years

▶ sonovaX – The foundation for our performance improvement

Leverage M&A to expand consumer access


Consumer Hearing (CH) business – Acquisition of Sennheiser Consumer Division

Strategic rationale:

- Joining forces in rapidly developing segment of **hearables with amplification**, jump-starting Sonova's own efforts
- Adding an **additional growth vector** by entering the fast-growing market of True Wireless headsets
- Expanding reach by capturing potential hearing instrument consumers **earlier on their journey**
- Gaining **access to new channels** and leveraging the strong Sennheiser brand
- **Leveraging the combined strengths** of Sonova's audiological expertise and Sennheiser's know-how in premium sound delivery
- Exploiting **significant synergies** in production, R&D and channel access



Sennheiser Consumer Division



► **First 9 months post closing we are on track with our Sennheiser business plan**

Leverage M&A to expand consumer access

Consumer Hearing Business – Speech enhanced hearables as new market opportunity under the Sennheiser brand


Market opportunity



Speech Enhanced Hearables are used to help consumers improve their comprehension in noisy environments.

How relevant is this product to you?

Base: n=1500*



Sennheiser Conversation Clear Plus earbuds




* Research conducted in US, CN, DE with consumers experiencing mild to moderate hearing loss (Consumer research on assistive listening devices, January 2022.)

► **First Sennheiser branded Speech Enhanced Hearable device launched in January 2023**




3

ESG strategy



Sonova's commitment to sustainable success

IntACT – Sonova's ESG Strategy



► ESG strategy clustered around four strategic areas

ESG highlights

Selected achievements highlighting progress towards our ESG targets



Environmental

- ▶ Committed to **science-based emissions reduction targets** for Scope 1, 2, and 3 CO₂e emissions (pending validation by SBTi)
- ▶ **Carbon neutral in our own operations** (Scope 1 and 2 CO₂e emissions) through energy efficiency measures, increasing our renewable energy ratio, and investing in certified offsetting projects in China, Vietnam, and Brazil



Social

- ▶ Across Sonova globally, **51.5% of all people managers are women**
- ▶ 97% of non-production or assembly employees have a **personal development plan**
- ▶ Global **employee health & wellbeing measures**, including hybrid working guidelines, leadership trainings on mental health, network of wellbeing champions



Governance

- ▶ Further advancing our **human rights due diligence** across our value chain in alignment with international frameworks, such as the UNGP and OECD Guidelines
- ▶ Implementing new solution for **supplier ESG risk assessment & monitoring**

- ▶ **Continuous progress on implementing Sonova's ESG strategy IntACT**


ESG ratings

Overview of Sonova's rating results for environmental, social, and governance (ESG) factors

Sonova ESG ratings


<p>B</p>	<p>AA</p>	<p>Low ESG risk</p>	<p>Member of Dow Jones Sustainability Indices Powered by the S&P Global CSA</p> <p>DJSI member</p>
<p>Status: Prime (C+ or better) Industry position: Top 2%</p> <p>Last rating update: 21 Nov 2022</p>	<p>Sonova received an MSCI ESG Rating of AA</p> <p>Last rating update: 28 Nov 2022</p>	<p>ESG Risk Rating 17.2</p> <p>Low Risk</p> <p>Legend</p> <ul style="list-style-type: none"> Industry (Healthcare) Rank Percentile: 42 / 630 7th Subindustry (Medical Devices) Rank Percentile: 1 / 226 1st <p>Last rating update: 6 Jul 2022</p>	<p>Member of indices: DJSI World & DJSI Europe</p> <p>77 /100 ESG score</p> <p>99th Industry percentile</p> <p>Last rating update: 9 Dec 2022</p>

► Major ESG rating agencies give Sonova industry-leading scores



4

Financial Information



Half Year 2022/23 – Highlights

Sound organic growth and positive contribution from acquisitions



Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

Half Year 2021/22 – Key financials

	iH 2022/23 CHF m	iH2021/22 CHF m	Δ % in LC vs. iH 2021/22	Δ % in CHF vs. iH 2021/22
Sales HI segment	1,703.2	1,465.6	+19.3%	+16.2%
<i>Sales HI business</i>	930.0	890.2	+5.3%	+4.5%
<i>Sales AC business</i>	640.1	575.4	+17.3%	+11.3%
<i>Sales CH business</i>	133.0	-	n/a	n/a
Sales CI segment	143.5	138.3	+3.0%	+3.8%
Total sales	1,846.6	1,603.8	+17.9%	+15.1%
Gross profit (adj.)	1,284.4	1,183.1	+12.3%	+8.6%
<i>Gross margin (adj.)</i>	<i>69.6%</i>	<i>73.8%</i>	<i>-350bps</i>	<i>-420bps</i>
OPEX (adj.)	886.3	776.7	+17.2%	+14.1%
<i>OPEX in % of sales (adj.)</i>	<i>48.0%</i>	<i>48.4%</i>	<i>-30bps</i>	<i>-40bps</i>
EBITA (adj.)	398.1	406.4	+3.0%	-2.0%
<i>EBITA margin (adj.)</i>	<i>21.6%</i>	<i>25.3%</i>	<i>-320bps</i>	<i>-380bps</i>
EPS (adj. in CHF)	4.90	4.86	+7.0%	+0.8%

Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

► **Growth in all businesses – Profitability affected by FX, mix, input costs and initial consolidation effects**

Hearing Instruments segment

Sound development in a challenging environment

Sales

CHF 1,703m

+19.3% vs. PY in LC

+5.2% organic growth

EBITA (adj.)

CHF 379m

+2.0% vs. PY in LC

Margin: 22.2%

Margin YOY: -380bps in LC

HI business

Sales:

CHF 930m

+5.3% vs. PY in LC

+5.3% organic growth

AC business

Sales:

CHF 640m

+17.3% vs. PY in LC

+5.1% organic growth

CH business

Sales:

CHF 133m

Segment sales

- Solid organic growth considering macroeconomic headwinds
- Successful launch of Phonak Lumity
- Strong contribution from the acquisitions in AC and Sennheiser Consumer Division

Segment profitability

- Subdued volume growth in specific higher price markets resulting in global ASP pressure
- Continued headwinds from elevated transportation and component costs – some signs of improvement
- Expected dilutive effect from first time consolidation of recent acquisitions

Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

► **Solid organic growth – Profitability affected by input costs and expected dilutive effect from M&A**

Cochlear Implants segment

Continued margin expansion with modest revenue growth

Sales
CHF 143.5m

+3.0% vs. PY in LC

EBITA (adj.)
CHF 19.5m

+25.2% vs. PY in LC

Margin: 13.6%

Margin YOY: +280bps in LC

System sales
CHF 93.3m

+3.6% vs. PY in LC

Upgrade sales
CHF 50.2m

+1.8% vs. PY in LC

Cochlear implant systems

- Momentum held back by supply shortages and continued hospital staffing challenges
- Headwind from injunction in DE related to patent dispute – sales restarted in October due to preliminary suspension of the injunction

Upgrades and accessories

- Solid growth despite high PY comparison base
- Ongoing success of recently launched sound processors, based on proven Marvel technology

Segment profitability


- Continued margin expansion despite modest YOY topline growth

Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

► **Solid growth in both systems and upgrades despite headwinds – Further profitability improvement**

Sales components


in CHF million



► Solid organic growth and strong contribution from acquisitions – Significant headwind from FX

EBITA components

in CHF million



Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

► **YOY margin development impacted by gross margin pressures, expected dilution from M&A and FX**

Operating Expenses

	iH 2022/23		iH 2021/22		Comments
	CHF m	Δ % in LC	CHF m		
Research & development (adj.) in % of sales	-119.2 6.5%	+3.8%	-114.8 7.2%		– Maintaining high investments in innovation
Sales & marketing (adj.) in % of sales	-613.1 33.2%	+22.7%	-517.4 32.3%		– ~70% of increase related to recent acquisitions – Affected by shift in business mix, due to expansion in AC, both through M&A and greenfield
General & administration (adj.) in % of sales	-154.0 8.3%	+8.9%	-144.1 9.0%		– ~90% of increase driven by acquisitions
Other income/expenses (adj.)	-0.0	NM	-0.5		
Total OPEX (adj.) in % of sales	-886.3 48.0%	+17.2%	-776.7 48.4%		
Adjustments	-5.5	NM	-11.0		– 1H 2021/22: restructuring and M&A costs – 1H 2022/23: restructuring, M&A and litigation cost
Total OPEX (reported) in % of sales	-891.8 48.3%	+16.3%	-787.8 49.1%		

Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

► Cost development reflecting recent acquisitions and good cost discipline

Financial information

Sonova Group – Total shareholder return (TSR) and cash deployment strategy

Sonova TSR strategy

1H 2022/23

1. Acquisitions

- Bolt-ons: CHF 70-100 million p.a.
- Strategic and technology acquisitions

- **Total M&A cash-out: more than CHF 85 million**, mainly spent for further AC network expansion

2. Attractive dividend

- Maintain payout ratio of around 40%

- **CHF 268 million distributed** with dividend up 37.5% YOY, representing a payout ratio of 41.0%

3. Healthy balance sheet

- Targeting net debt/EBITDA ratio of 1.0-1.5x

- Equity ratio of 38.5%
- Net Debt/EBITDA ratio of 1.5x

4. Share buyback

- New three-year buyback program of up to CHF 1.5 billion


- New buyback program started in April 2022
- **Approximately CHF 300 million bought back**

► **TSR strategy aimed at creating shareholder value through three avenues**



5

Outlook



Considerations for 2H 2022/23

Hearing Care Market

- Inflationary pressures expected to persist
- Consumer sentiment believed to remain muted
- Slow start into the period signals expected sequential market slowdown vs. 1H and implies limited market growth in 2H
- Market momentum subject to higher-than-normal volatility, reflecting macroeconomic uncertainty

Sonova

- Guidance remains in place, reflecting current market assumptions – expecting to reach the lower end of the FY 22/23 range
- Lumity platform and contribution from recent price increases to lift average selling price (ASP) for the entire period
- Renewal of large contract with individual client in the US unlikely – temporary suspension ongoing
- Further expanding AC network through bolt-ons, additionally planned HYSOUND acquisition to add ~200 POS
- CH business to benefit from significantly higher sales during the important Christmas season
- Gradual easing of supply chain constraints and transportation costs expected

► **Guidance remains in place – Expecting to reach the lower end of the FY 2022/23 range**

Outlook

Guidance and mid-term target

In LC	Guidance FY 2022/23	Mid-term Target
Sales growth	+15% to +19%	+6% to +9% p.a.
adj. EBITA growth	+6% to +10%	+7% to +11% p.a.


Note: adj. refers to adjusted figures; for details, please refer to Appendix – Non-GAAP adjustments.

- Attractive fundamentals of hearing care market remain intact
- Expecting to reach the lower end of the guidance ranges, reflecting a slowdown of the global hearing care market due to the ongoing macroeconomic challenges
- Reflecting exchange rates as of the end of December 2022, reported sales growth in Swiss francs are expected to be reduced by ~3-4 %-pts and adj. EBITA growth in Swiss francs to be negatively affected by ~5-6 %-pts in FY 2022/23





6

Appendix



Appendix

Performance history



Sales growth reported	+10.4%	+4.4%	+5.6%	-10.8%	+29.3%	15.1%
Sales growth in LC	+9.0%	+4.1%	+8.7%	-6.8%	+29.0%	17.9%
Organic sales growth in LC	+3.8%	+4.9%	+8.1%	-7.1%	+26.6%	5.0%
EBITA Margin (adj.)	20.8%	21.5%	21.2%	23.2%	25.1%	21.6%

Note: adj. refers to adjusted figures; for details, please refer to the respective annual report

► **Solid sales growth across all businesses despite slower growth in specific higher price markets**

Appendix


Sales by segment and sales components

	iH 2022/23			iH 2021/22		
	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC
<i>HI business</i>	930.0	+4.5%	+5.3%	890.2	+46.5%	+46.2%
<i>AC business</i>	640.1	+11.3%	+17.3%	575.4	+51.9%	+48.0%
<i>CH business</i>	133.0	n/a	n/a	-	n/a	n/a
HI segment	1,703.2	+16.2%	+19.3%	1,465.6	+48.6%	+46.9%
CI segment	143.5	+3.8%	+3.0%	138.3	+66.4%	+67.3%
Total Sonova	1,846.6	+15.1%	+17.9%	1,603.8	+49.9%	+48.5%
Δ organic	+80.2	-	+5.0%	+498.9	-	+46.6%
Δ acquisitions	+207.4	-	+12.9%	+19.8	-	+1.8%
Δ disposals	-0.4	-	-0.0%	-0.2	-	-0.0%
Δ FX	-44.4	-2.8%	-	+15.7	+1.5%	-

Appendix

Sales by regions and key markets

	iH 2022/23			iH 2021/22	
	CHF m	Δ % in LC	% Group sales	CHF m	% Group sales
EMEA	879.8	+14.9%	47%	830.6	52%
USA	602.7	+14.2%	33%	499.8	31%
Americas (excl. USA)	140.1	+16.1%	8%	116.9	7%
Asia / Pacific	224.0	+47.1%	12%	156.6	10%
Total Sonova	1,846.6	+17.9%	100%	1,603.8	100%




- Robust development in key markets incl. DE, NL and Nordics despite macroeconomic headwinds
- Growth held back by market decline in FR after reimbursement change in 2021 and softness in the UK private market
- Growth held back by declining volumes in the US private market – partly offset by good growth in the VA channel
- Development supported by the recent acquisitions in AC, in particular Alpaca Audiology
- Americas (excl. the US) helped by acquisitions – growth supported by solid performance in CA
- APAC sales lifted by acquisitions, incl. Sennheiser – added to by low comparison base due to lockdowns in AU in PY

► **Growth across all regions, supported by acquisitions – Market headwinds in the US**

Appendix

Sonova Group – Operating Free Cash Flow

in CHF million



- **NWC:** Nearly half of the increase driven by lower payables from payments related to a safety inventory build-up at the end of FY 21/22; remainder primarily from lower accruals associated to payment timing for various business projects as well as lower accruals for equity-based payments due to a lower share price in 2022.
- **Build-up in working capital for Consumer Hearing business:** Acquisition of Sennheiser Consumer Division without receivables and payables.
- **Other items:** Increased lease payments related to AC network expansion, movements in financial assets and lower financial expenses.

Appendix

Cash flow statement

	1H 2022/23		1H 2021/22
	CHF m	Δ % in CHF	CHF m
Income before taxes	350.5	-0.7%	353.0
<i>Depreciation & amortization</i>	119.0	+13.5%	104.8
<i>Working capital</i>	-142.1	+195.4%	-48.1
<i>Other cash effects</i>	-2.1	-119.8%	10.6
<i>Tax paid</i>	-37.3	+19.2%	-31.3
<i>Financial result</i>	15.0	-27.5%	20.7
Operating cash flow	303.0	-26.1%	409.8
<i>Payments for lease liabilities</i>	-39.5	+19.0%	-33.2
<i>Capex</i>	-68.7	+80.1%	-38.1
<i>Other movements in financial assets</i>	-9.6	+708.3%	-1.2
Operating free cash flow	185.3	-45.1%	337.3
<i>Net M&A</i>	-85.7	+16.3%	-73.7
Free cash flow	99.5	-62.3%	263.6
Cash flow from financing activities	-463.6	NM	-546.6

Appendix

Balance sheet

CHF m	30 Sep 2022	30 Sep 2021	Comments
Days sales outstanding (DSO)	51	54	– Continued strong receivable collection
Days inventory outstanding (DIO)	148	149	– Reduction from process improvement vs. year end – Impacted by safety stock and product launches
Capital employed	3,498.1	2,917.2	– Higher intangibles from acquisitions
ROCE (reported)	23.4%	27.3%	– YOY development driven by acquisitions and profit development
Net debt	1,497.3	345.3	– Increase related to share buyback program, dividend payments and step-up in M&A
Net debt/EBITDA	1.5x	0.3x	

Note: DSO and DIO calculated on a 90-day basis; net debt/EBITDA ratio calculated based on net debt as of 30 September 2022, divided by 12-months rolling reported EBITDA.

► Continued strong receivable collection – Higher leverage as a result of share buyback program and M&A

Appendix

Non-GAAP adjustments

in CHF million	iH 2022/23	Adjustments				Total	iH 2022/23
	Reported	① Restructuring costs	② Transaction & integration costs	③ Patent litigation		Adjusted	
Sales	1,846.6	-	-	-	-	1,846.6	
Cost of sales	-563.0	+0.7	-	-	+0.7	-562.2	
Gross profit	1,283.7	+0.7	-	-	+0.7	1,284.4	
<i>Research & development</i>	-119.2	+0.0	-	-	+0.0	-119.2	
<i>Sales & marketing</i>	-617.4	+2.6	+1.6	-	+4.2	-613.1	
<i>General & administration</i>	-155.3	-0.6	+0.9	+1.0	+1.3	-154.0	
<i>Other income/(expenses)</i>	-0.0	-	-	-	-	-0.0	
Total OPEX	-891.8	+2.0	+2.5	+1.0	+5.5	-886.3	
EBITA	391.8	+2.8	+2.5	+1.0	+6.3	398.1	
EPS (in CHF)	4.81	+0.03	+0.04	0.02	+0.09	4.90	

Note: positive values indicate a positive impact on the adjusted vs. the respective reported financial metric and vice versa.

① **Restructuring:** costs related to structural optimization initiatives

② **Transaction & integration:** costs related to the acquisition and integration of the Sennheiser Consumer Division and Alpaca Audiology

③ **Patent litigation:** costs related to patent litigation with MED-EL

Appendix

Sonova Group – FX impact on sales and margins

USD/CHF




EUR/CHF



	Rate	Sales	EBITA
USD/CHF	+/- 5%	+/- CHF 63 million	+/- CHF 17 million
EUR/CHF	+/- 5%	+/- CHF 64 million	+/- CHF 24 million

Appendix

Sonova Group – Sales by currency and FX rates



	iH-21/22	iH-22/23	Effect iH-22/22	2H-21/22	FY-21/22	Spot Oct-2022
USD	0.91	0.97	+	0.92	0.92	1.00
EUR	1.09	1.00	-	1.05	1.07	0.99
GBP	1.27	1.17	-	1.24	1.26	1.16
CAD	0.74	0.75	+	0.73	0.73	0.73
AUD	0.69	0.67	-	0.67	0.68	0.64
BRL	0.17	0.19	+	0.16	0.17	0.19
JPY 100	0.83	0.72	-	0.81	0.82	0.67

Investor relations contacts






Thomas Bernhardsgruetter
Senior Director Investor Relations

 +41 58 928 33 44
 +41 79 618 28 07
 Thomas.Bernhardsgruetter@sonova.com





Jessica Grassi
Director Investor Relations




 +41 58 928 33 22
 +41 79 416 28 76
 Jessica.Grassi@sonova.com



Nicole Jenni
Investor Relations Associate

 +41 58 928 33 21
 Nicole.Jenni@sonova.com

Sonova Group Headquarters

 Laubisrütistrasse 28
CH-8712 Stäfa
Switzerland
 ir@sonova.com
 Switchboard: +41 58 928 01 01